On October 20, 2021 PTC (Nasdaq: PTC) reported that it will release its fiscal 2021 fourth quarter and full year results on Wednesday, November 3rd after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, November 3rd at 5pm Eastern Time (Press release, PTC Therapeutics, OCT 20, 2021, View Source [SID1234591617]). The earnings press release, accompanying earnings presentation, and financial data tables will be accessible prior to the conference call and webcast on the Investor Relations section of the Company’s web site at PTC Investor Relations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

What: PTC Fiscal Q4’21 Conference Call and Webcast

When: Wednesday, November 3rd, 2021 at 5:00pm (ET)

Webcast: View Source

Replay: To access the replay via webcast, please visit View Source.

Please note that statements made on the conference call and webcast are as of the date of the conference call and webcast and PTC does not assume any obligation to update any statements made live or the archived call. Matters discussed may include forward-looking statements about PTC’s anticipated financial results and growth, as well as about the development of products and markets, which are based on current plans and assumptions. Actual results in future periods may differ materially from current expectations due to a number of risks and uncertainties, including those described from time to time in reports filed by PTC with the U.S. Securities and Exchange Commission, including PTC’s most recent reports on Form 10-K and 10-Q.

On October 20, 2021 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) reported that it will host a live webcast on Wednesday, November 3rd at 11:30 a.m. Eastern Time to discuss its third quarter 2021 financial results and report on pipeline and business progress (Press release, Ionis Pharmaceuticals, OCT 20, 2021, View Source [SID1234591616]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the webcast at View Source A webcast replay will be available for a limited time at the same address.

On October 20, 2021 NextEra Energy, Inc. (NYSE: NEE) reported that has posted its third-quarter 2021 financial results in a news release available on the company’s website by accessing the following link: www.NextEraEnergy.com/FinancialResults (Press release, Nextera, OCT 20, 2021, View Source [SID1234591615]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jim Robo, chairman and chief executive officer of NextEra Energy, Rebecca Kujawa, executive vice president, finance and chief financial officer of NextEra Energy, and other members of the company’s senior management team will discuss the company’s third-quarter 2021 financial results during an investor presentation to be webcast live, beginning at 9 a.m. ET today. The listen-only webcast will be available on NextEra Energy’s website by accessing the following link: www.NextEraEnergy.com/FinancialResults. Also discussed during the investor presentation will be financial results for NextEra Energy Partners, LP (NYSE: NEP). A replay will be available for 90 days by accessing the same link as listed above.

On October 20, 2021 Atlas Corp. ("Atlas") (NYSE: ATCO) reported its financial results for the quarter ended September 30, 2021, after the market close on Monday, November 8, 2021 (Press release, Atlas Therapeutics, OCT 20, 2021, View Source [SID1234591614]). Atlas plans to host a conference call for all shareholders and interested parties at 8:30 a.m. Eastern Time (ET) on Tuesday, November 9, 2021, to discuss the results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Information:

Conference ID:

3042969

To access the live webcast of the conference call, go to atlascorporation.com and click on "Investor Relations" then "Events & Presentations" for the link. The webcast will be archived on the website for one year.

A replay will be available approximately two hours following the conclusion of the call and accessible until November 23, 2021. The replay telephone numbers are as follows: US/Canada +1 (855) 859-2056 or +1 (800) 585-8367 and International +1 (404) 537-3406, and the replay passcode is: 3042969.

On October 20, 2021 CytoReason, an Israeli company developing computational disease models for more efficient drug discovery and development, reported a collaboration with German multinational science and technology company, Merck KGaA, Darmstadt, Germany, to profile one of its leading immuno-oncology drugs (Press release, Merck KGaA, OCT 20, 2021, View Source [SID1234591613]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Multiple drugs created to cure the same disease have varying effects on certain patient populations depending on the drug’s mechanism of action (MoA) and on patients’ characteristics. CytoReason will use its machine learning platform and proprietary computational disease models to verify Merck KGaA, Darmstadt, Germany’s therapeutic hypothesis, providing a deeper analysis of the drug’s MoA.

The company will analyze data from hundreds of patients from phase 1 and 2 studies to identify relevant patient populations, as well as prioritize tumor types for which the drug may be most effective against.

"We are thrilled to be working with the talented team at Merck KGaA, Darmstadt, Germany," said David Harel, CEO and Co-founder of CytoReason. "Merck KGaA, Darmstadt, Germany’s rich medical database and expertise in immuno-oncology will enable us to help create more accurate models of the disease with CytoReason’s advanced AI technology. This collaboration might help identify which type of tumor the drug will be most effective for, and has the potential to save the lives of millions who suffer from cancer."